News
Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio.
FEATURED STORIES
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Researchers at the Wuhan Institute of Virology (WIV), which is potentially linked to the origins of COVID-19, reported the discovery of a novel DNA virus in animals in the journal Virologica Sinica.
Day One Biopharmaceuticals aims to provide a business solution to a moral problem: the inequity in pediatric oncology drug development.
Clover’s SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines.
The University of Michigan and the University of South Florida have filed a lawsuit against Novartis, alleging the company’s cardiac drug, Entresto, infringes a cocrystal patent held by both universities.
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
In the wake of the COVID-19 pandemic, several Western nations are investing heavily in rapidly developing drugs to treat populations when new pandemics emerge.
The life science field offers a wealth of opportunities, even for those working outside of the field. Here are six life science jobs that don’t require industry experience.
The long-awaited review of problematic opioid prescribing is taking longer than observers had hoped.
Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival.
Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.